SCHEMBL5459989

SCHEMBL5459989

NC(=O)c1c(NC(=O)NCCC2=CCCCC2)sc2c1CCOC2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 1/20 0.50
RAB9A P51151 4/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
NPC1 O15118 3/20 0.43
GAA P10253 1/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
PTPRC P08575 1/20 0.43
PTPN2 P17706 1/20 0.43
PTPN1 P18031 1/20 0.43
PTPRB P23467 1/20 0.43
PTPRE P23469 1/20 0.43
FLT3 P36888 2/20 0.42
MEN1 O00255 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C19 P33261 1/20 0.42
KMT2A Q03164 1/20 0.42
CNR2 P34972 5/20 0.42
EPHX1 P07099 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5451580 0.81 CFTR (0.56) CFTRRAB9ASMN1; SMN2PTPRCPTPN2
SCHEMBL5467760 0.80 LMNA (0.54) CFTRRAB9ASMN1; SMN2NPC1PTPRC
SCHEMBL5455772 0.79 CFTR (0.54) CFTRRAB9ASMN1; SMN2PTPRCPTPN2
SCHEMBL5460163 0.79 FLT3 (0.58) CFTRFLT3MEN1KMT2ACNR2
SCHEMBL5459433 0.78 CFTR (0.55) CFTRPTPRCPTPN2PTPN1PTPRB
SCHEMBL5450850 0.78 CFTR (0.58) CFTRRAB9ANPC1PTPRCPTPN2
SCHEMBL5453229 0.77 CFTR (0.51) CFTRRAB9ANPC1PTPRCPTPN2
SCHEMBL5465529 0.76 CFTR (0.53) CFTRRAB9ASMN1; SMN2PTPRCPTPN2
SCHEMBL5459377 0.75 CFTR (0.60) CFTRRAB9ANPC1PTPRCPTPN2
SCHEMBL5460329 0.75 CFTR (0.62) CFTRRAB9ASMN1; SMN2PTPRCPTPN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 CFTR 2030/4885RAB9A 948/4885SMN1; SMN2 2157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.